tradingkey.logo

Dare Bioscience Inc

DARE
View Detailed Chart
1.820USD
-0.010-0.55%
Close 11/10, 16:00ETQuotes delayed by 15 min
16.44MMarket Cap
LossP/E TTM

Dare Bioscience Inc

1.820
-0.010-0.55%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.55%

5 Days

-5.21%

1 Month

-14.15%

6 Months

-37.46%

Year to Date

-41.67%

1 Year

-56.25%

View Detailed Chart

TradingKey Stock Score of Dare Bioscience Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company shows weak stock market performance, in line with its weak fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dare Bioscience Inc's Score

Industry at a Glance

Industry Ranking
107 / 159
Overall Ranking
291 / 4611
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
10.750
Target Price
+487.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dare Bioscience Inc Highlights

StrengthsRisks
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Growing
The company is in a growing phase, with the latest annual income totaling USD 9.78K.
Overvalued
The company’s latest PE is -0.18, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.00M shares, decreasing 32.47% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 71.80K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.66.

Dare Bioscience Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Dare Bioscience Inc Info

Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Ticker SymbolDARE
CompanyDare Bioscience Inc
CEOMs. Sabrina Martucci Johnson
Websitehttps://www.darebioscience.com/
KeyAI